thyroid cancer
Eli Lilly to Share With Regulators Data on Retevmo Besting Standard Drugs in Thyroid Cancer Patients
The Phase III study data showing Retevmo improved progression-free survival in patients with RET-mutant tumors may support conversion from accelerated to full approval.
Roche, Blueprint Medicines Withdraw Gavreto in RET-Mutant Medullary Thyroid Cancer in US
Genentech has decided it will no longer pursue the confirmatory trial for Gavreto in this setting due to feasibility.
Roche to Terminate Gavreto Deal With Blueprint Medicines
Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.
While Geisinger sees value in identifying at-risk patients and diagnosing cancer early, some experts are concerned about overtreatment.
OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing
The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.